(Q54566712)

English

First-line therapy for CML: nilotinib comes of age.

scientific article

In more languages

edit

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21856227

title

First-line therapy for CML: nilotinib comes of age. (English)

1 reference

stated in

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21856227

author name string

Jeff Davies

series ordinal

1

1 reference

stated in

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21856227

publication date

17 August 2011

1 reference

stated in

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21856227

published in

Lancet Oncology Commission

1 reference

stated in

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21856227

volume

12

1 reference

stated in

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21856227

issue

9

1 reference

stated in

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21856227

page(s)

826-827

1 reference

stated in

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21856227

cites work

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970228-5

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970228-5

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970228-5

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970228-5

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970228-5

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970228-5

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

DOI

10.1016/S1470-2045(11)70228-5

1 reference

stated in

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21856227

PubMed ID

21856227

1 reference

stated in

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21856227

(Q54566712)

First-line therapy for CML: nilotinib comes of age.

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)